Latest News on ILMN

Financial News Based On Company


Advertisement
Advertisement

Should Boston Scientific Stock Be in Your Portfolio Right Now?

https://www.zacks.com/stock/news/2741539/should-boston-scientific-stock-be-in-your-portfolio-right-now
BSX's global expansion and MedSurg growth boost Q2 momentum, though currency and macro headwinds weigh on the same.

Icahn Hedge Fund's Q2 Moves: Centuri Stake Soars, JetBlue Held, 2 Positions Exited - SandRidge Energy ( NYSE:SD ) , JetBlue Airways ( NASDAQ:JBLU ) , Centuri Holdings ( NYSE:CTRI ) , Intl Flavors & Fragrances ( NYSE:IFF )

https://www.benzinga.com/markets/hedge-funds/25/08/47166066/icahn-hedge-funds-q2-moves-centuri-stake-soars-jetblue-held-2-positions-exited
Icahn boosts Centuri stake 158%, keeps JetBlue and utilities steady. Portfolio shifts favor infrastructure, utilities, and cash flow over cyclical or speculative bets. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.

NICE Stock Stops Being Nice, Has A Bearish Breakdown - Illumina ( NASDAQ:ILMN ) , NICE ( NASDAQ:NICE )

https://www.benzinga.com/markets/equities/25/08/47156699/nice-stock-stops-being-nice-has-a-bearish-breakdown
NICE Ltd. NICE has entered Phase 9 of its 18-phase Adhishthana cycle on the monthly chart, and the technical picture has deteriorated. The stock appears to have broken its Adhishthana Cakra to the downside, a signal that often precedes a long stretch of consolidation and weakness.

TMO Receives FDA Approval for Oncomine Dx Target Test

https://www.zacks.com/stock/news/2716721/tmo-receives-fda-approval-for-oncomine-dx-target-test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.

Cathie Wood's Thursday Bet: ARK Just Bought $31 Million Worth Of Falling Deere Stock, Also Loads Up On Block, Robinhood Shares - ARK Innovation ETF ( BATS:ARKK )

https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/08/47145329/cathie-woods-thursday-bet-ark-just-bought-31-million-worth-of-falling-deere-stock-also
Ark Invest, led by Cathie Wood, made significant trades on Thursday - focusing on Deere & Co. DE, Block Inc. XYZ and Robinhood Markets Inc. HOOD. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started WiserAdvisorGet matched with a trusted, local financial advisor for ...
Advertisement

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer - BioStem Technologies ( OTC:BSEM ) , Illumina ( NASDAQ:ILMN )

https://www.benzinga.com/pressreleases/25/08/g47137516/biostem-technologies-appoints-brandon-poe-as-chief-financial-officer
POMPANO BEACH, Fla., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- BioStem Technologies, Inc. ( "BioStem" or the "Company" ) BSEM, a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the ...

KMDA vs. ILMN: Which Stock Is the Better Value Option?

https://www.zacks.com/stock/news/2712651/kmda-vs-ilmn-which-stock-is-the-better-value-option
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada ( KMDA Quick QuoteKMDA - ) and Illumina ( ILMN Quick QuoteILMN - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

https://www.zacks.com/stock/news/2707288/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Illumina Settles With DOJ, Veterans To End Whistleblower Lawsuit - Illumina ( NASDAQ:ILMN )

https://www.benzinga.com/news/legal/25/08/46918066/illumina-settles-with-doj-veterans-to-end-whistleblower-lawsuit
Illumina will pay $9.8 million, including $4.3 million in restitution, to settle false claims related to software vulnerabilities. Whistleblower will receive $1.9 million from the settlement under the False Claims Act. Get special access to three exclusive "Top 10 Stocks" power lists today, ...

Illumina ( ILMN ) Reliance on International Sales: What Investors Need to Know

https://www.zacks.com/stock/news/2667423/illumina-ilmn-reliance-on-international-sales-what-investors-need-to-know
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Advertisement

What Does the Market Think About Illumina? - Illumina ( NASDAQ:ILMN )

https://www.benzinga.com/insights/short-sellers/25/08/46832306/what-does-the-market-think-about-illumina
Illumina's ILMN short percent of float has risen 12.85% since its last report. The company recently reported that it has 7.89 million shares sold short, which is 7.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.56 days to cover their ...

Illumina ( ILMN ) Q2 2025 Earnings Call Transcript

https://www.fool.com/earnings/call-transcripts/2025/08/03/illumina-ilmn-q2-2025-earnings-call-transcript/
Image source: The Motley Fool.Thursday, July 31, 2025 at 8:30 p.m. ETChief Executive Officer - Jacob ThaysenContinue reading ...

Illumina ( ILMN ) Q2 EPS Jumps 9%

https://www.fool.com/data-news/2025/08/01/illumina-ilmn-q2-eps-jumps-9/
Illumina ( NASDAQ:ILMN ) , a global leader in DNA sequencing and genomics, released its second quarter results on July 31, 2025, for the fiscal 2025 period. The results were notable for beating analyst expectations on both non-GAAP EPS and GAAP revenue.

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results - Illumina ( NASDAQ:ILMN )

https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46800842/these-analysts-boost-their-forecasts-on-illumina-following-upbeat-results
Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday. The company posted quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.01 per share. The company reported quarterly sales of $1.059 billion which beat the analyst ...

Illumina: A 5.2 Rating Amid Challenges and Opportunities

https://www.fool.com/investing/2025/07/31/illumina-a-52-rating-amid-challenges-and-opportuni/
Explore the exciting world of Illumina ( NASDAQ: ILMN ) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of Jul. 9, 2025.
Advertisement

Illumina ( ILMN ) Q2 Earnings and Revenues Surpass Estimates

https://www.zacks.com/stock/news/2645710/illumina-ilmn-q2-earnings-and-revenues-surpass-estimates
Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

https://www.zacks.com/stock/news/2638574/3-genomics-stocks-worth-adding-to-your-portfolio-in-2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...

Gear Up for Illumina ( ILMN ) Q2 Earnings: Wall Street Estimates for Key Metrics

https://www.zacks.com/stock/news/2638328/gear-up-for-illumina-ilmn-q2-earnings-wall-street-estimates-for-key-metrics
Besides Wall Street's top-and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

CRISPR Therapeutics AG ( CRSP ) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

https://www.zacks.com/stock/news/2628943/crispr-therapeutics-ag-crsp-may-report-negative-earnings-know-the-trend-ahead-of-q2-release
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CorMedix ( CRMD ) Soars 5.1%: Is Further Upside Left in the Stock?

https://www.zacks.com/stock/news/2612957/cormedix-crmd-soars-51-is-further-upside-left-in-the-stock
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Advertisement

Illumina ( ILMN ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

https://www.zacks.com/stock/news/2612543/illumina-ilmn-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cathie Wood Buys The Nvidia Dip Amid Panic Over Stargate Project: Ark Swoops Up $2 Million Worth Of Hot AI Stock - ARK Space Exploration & Innovation ETF ( BATS:ARKX ) , NVIDIA ( NASDAQ:NVDA )

https://www.benzinga.com/news/25/07/46563331/cathie-wood-buys-the-nvidia-dip-amid-panic-over-stargate-project-ark-swoops-up-2-million-worth-of-hot-ai-sto
On Tuesday, Cathie Wood's Ark Invest made a notable move by purchasing shares of NVIDIA Corp NVDA amid concerns surrounding a significant AI project.

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

https://www.zacks.com/stock/news/2602910/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?

https://www.zacks.com/stock/news/2602456/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now
Smart Beta ETF report for ...

Illumina Stock: What Went Wrong And Why It's Best To Stay Away - Illumina ( NASDAQ:ILMN )

https://www.benzinga.com/markets/equities/25/07/46463747/illumina-stock-what-went-wrong-and-why-its-best-to-stay-away
Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.
Advertisement

HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

https://www.zacks.com/stock/news/2582974/hrmy-vs-ilmn-which-stock-should-value-investors-buy-now
HRMY vs. ILMN: Which Stock Is the Better Value Option?

Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?

https://www.zacks.com/stock/news/2582291/will-robust-medsurg-performance-fuel-boston-scientifics-q2-earnings
BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.

Agenus ( AGEN ) Surges 19.3%: Is This an Indication of Further Gains?

https://www.zacks.com/stock/news/2579673/agenus-agen-surges-193-is-this-an-indication-of-further-gains
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's How Much a $1000 Investment in Agilent Technologies Made 10 Years Ago Would Be Worth Today

https://www.zacks.com/stock/news/2579421/heres-how-much-a-1000-investment-in-agilent-technologies-made-10-years-ago-would-be-worth-today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

iRhythm Technologies Announces Board Member Retirements and New Director Appointments

https://www.globenewswire.com/news-release/2025/07/07/3111011/0/en/iRhythm-Technologies-Announces-Board-Member-Retirements-and-New-Director-Appointments.html
SAN FRANCISCO, July 07, 2025 ( GLOBE NEWSWIRE ) -- iRhythm Technologies, Inc. ( NASDAQ:IRTC ) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and ...
Advertisement

iRhythm Technologies Announces Board Member Retirements and New Director Appointments - Absci ( NASDAQ:ABSI ) , Alphatec Holdings ( NASDAQ:ATEC )

https://www.benzinga.com/pressreleases/25/07/g46272339/irhythm-technologies-announces-board-member-retirements-and-new-director-appointments
SAN FRANCISCO, July 07, 2025 ( GLOBE NEWSWIRE ) -- iRhythm Technologies, Inc. IRTC , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph ...

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

https://www.zacks.com/stock/news/2559456/incyte-gains-92-in-three-months-buy-hold-or-sell-the-stock
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.

Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?

https://www.zacks.com/stock/news/2555854/tempus-ais-data-business-keeps-scaling-up-can-the-growth-pace-last
TEM is scaling fast. Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.

Laboratory Information Management System Market worth US$5.19 billion by 2030 with 12.5% CAGR | MarketsandMarkets™.

https://www.benzinga.com/pressreleases/25/06/g46137380/laboratory-information-management-system-market-worth-us-5-19-billion-by-2030-with-12-5-cagr-marke
Delray Beach, FL, June 27, 2025 ( GLOBE NEWSWIRE ) -- The global laboratory information management system market, valued at US$2.54 billion in 2024, stood at US$2.88 billion in 2025 and is projected to advance at a resilient CAGR of 12.5% from 2025 to 2030, culminating in a forecasted valuation ...

3 Promising Genomics Stocks to Keep an Eye On in 2025

https://www.zacks.com/stock/news/2555713/3-promising-genomics-stocks-to-keep-an-eye-on-in-2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Advertisement

Illumina Stock May Benefit From New Agreement to Acquire SomaLogic

https://www.zacks.com/stock/news/2554296/illumina-stock-may-benefit-from-new-agreement-to-acquire-somalogic
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.

FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Allot ( NASDAQ:ALLT ) , AST SpaceMobile ( NASDAQ:ASTS )

https://www.benzinga.com/trading-ideas/movers/25/06/46093477/fedex-issues-soft-guidance-joins-torrid-holdings-allot-and-other-big-stocks-moving-lower-in-
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of FedEx Corporation FDX fell sharply in today's pre-market trading following soft first-quarter guidance.

Cathie Wood Drops $6.5 Million On SHOP And ABNB, Betting You Won't Stop Shopping Or Traveling - ARK Fintech Innovation ETF ( BATS:ARKF ) , Airbnb ( NASDAQ:ABNB )

https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46086884/cathie-wood-drops-6-5-million-on-shop-and-abnb-betting-you-wont-stop-shopping-or-trave
Cathie Wood-led Ark Invest made significant trades on Tuesday, spotlighting its strategic acquisitions of Shopify Inc. SHOP and Airbnb Inc. ABNB. These trades reflect Ark's continued interest in high-growth technology and e-commerce sectors.

Geopolitics, Tariffs Offset AI Prospects in Semis: 2 Stocks

https://www.zacks.com/commentary/2546585/geopolitics-tariffs-offset-ai-prospects-in-semis-2-stocks
Despite secular growth prospects for the Semiconductor - General industry, rich valuations keep us on the sidelines. NVDA and TXN are worth tracking.

SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push - Illumina ( NASDAQ:ILMN ) , Standard BioTools ( NASDAQ:LAB )

https://www.benzinga.com/m-a/25/06/46056588/somalogic-acquisition-worth-350-million-marks-next-step-in-illuminas-advanced-biomarker-push
Illumina to pay $350 million in cash and up to $75 million in milestones to acquire SomaLogic. Deal expected to close in H1 2026; profitability anticipated by 2027. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. On Monday, Illumina, Inc.
Advertisement

Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday - Circle Internet Group ( NYSE:CRCL ) , AIRO Group Holdings ( NASDAQ:AIRO )

https://www.benzinga.com/trading-ideas/movers/25/06/46054785/kroger-posts-better-than-expected-earnings-joins-couchbase-carmax-and-other-big-stocks-movin
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Monday. Shares of Tesla, Inc. TSLA rose sharply during Monday's session amid the Robotaxi launch in Austin, TX.

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

https://www.globenewswire.com/news-release/2025/06/23/3103269/0/en/Standard-BioTools-Enters-Next-Phase-of-Transformation-with-Strategic-Sale-of-SomaLogic-to-Illumina.html
Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments. $350 Million In Upfront Cash ...

FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?

https://www.zacks.com/stock/news/2520783/ftre-vs-ilmn-which-stock-should-value-investors-buy-now
FTRE vs. ILMN: Which Stock Is the Better Value Option?

Here's How Much You'd Have If You Invested $1000 in Agilent Technologies a Decade Ago

https://www.zacks.com/stock/news/2514647/heres-how-much-youd-have-if-you-invested-1000-in-agilent-technologies-a-decade-ago
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics

https://www.zacks.com/stock/news/2507024/incyte-stock-rises-on-qiagen-deal-to-advance-blood-cancer-diagnostics
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
Advertisement

Saudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025

https://www.benzinga.com/pressreleases/25/06/g45960395/saudia-arabia-introduces-strategic-healthcare-vision-and-global-partnerships-at-bio-2025
BOSTON, June 16, 2025 ( GLOBE NEWSWIRE ) -- Saudi Arabia officially opened its national pavilion today at the BIO International Convention 2025, marking a milestone moment in its journey to become a global biotechnology hub.

QGEN Stock Rises in After Market Following Partnership With Incyte

https://www.zacks.com/stock/news/2503105/qgen-stock-rises-in-after-market-following-partnership-with-incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.

Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach

https://www.zacks.com/stock/news/2498512/tempus-ais-expanding-ties-boost-novel-rd-efforts-and-market-reach
TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.

Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Datadog ( NASDAQ:DDOG ) , Academy Sports ( NASDAQ:ASO )

https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45882863/datadog-to-rally-around-17-here-are-10-top-analyst-forecasts-for-wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised Lumentum Holdings Inc. LITE price target from $100 to $105.

Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™.

https://www.benzinga.com/pressreleases/25/06/g45881467/genomics-market-to-hit-us-66-8-billion-by-2029-with-9-4-cagr-marketsandmarkets
Delray Beach, FL, June 11, 2025 ( GLOBE NEWSWIRE ) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of ...
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion